Summary
Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on November 6, 2013, to report its financial results for the quarter ended September 30, 2013. The filing primarily consists of a press release containing these financial results. Investors should note that this information is furnished, not filed, meaning it does not carry the same liabilities as a fully filed document under Section 18 of the Exchange Act. The key takeaway for investors from this filing is the company's financial performance for the third quarter of 2013. While the 8-K itself does not detail the results, it directs readers to Exhibit 99.1, the associated press release, which would contain the specifics of revenue, expenses, net income/loss, and any other significant financial metrics for the period. This information is crucial for understanding the company's operational health and progress.
Key Highlights
- 1Company reported financial results for the quarter ended September 30, 2013.
- 2The filing is an 8-K, indicating a significant event or change.
- 3The primary content is a press release (Exhibit 99.1) containing the financial results.
- 4Information provided is furnished, not formally filed, under Section 18 of the Exchange Act.
- 5This filing serves as a notification mechanism for investors regarding Q3 2013 financial performance.